Hypertension after Kidney Transplantation: Clinical Significance and Therapeutical Aspects

Galina Severova-Andreevska1, Ilina Danilovska1, Aleksandar Sikole1, Zivko Popov2,3, Ninoslav Ivanovski3,4

1University Clinic of Nephrology, Medical Faculty, Ss Cyril and Methodius University of Skopje, Skopje, Republic of Macedonia; 2Macedonian Academy for Science and Arts, Skopje, Republic of Macedonia; 3Zan Mitrev Clinic, Skopje, Republic of Macedonia; 4Ss Cyril and Methodius University of Skopje, Skopje, Republic of Macedonia

Abstract

Most of the kidney transplanted patients develop arterial hypertension after renal transplantation. Together with very well-known and usual risk factors, post-transplant hypertension contributes to the whole cardiovascular morbidity and mortality in the kidney transplant population. The reasons of post-transplant hypertension are factors related to donors and recipients, immunosuppressive therapy like Calcineurin Inhibitors (CNI) and surgery procedures (stenosis and kinking of the renal artery and ureteral obstruction). According to Eighth National Committee (JNC 8) recommendations, blood pressure > 140/90 mmHg is considered as hypertension. The usual antihypertensive drugs used for the control of hypertension are Calcium channel blockers (CCB), Angiotensin-converting enzyme (ACE) inhibitors, Angiotensin II receptor blockers (ARB), B1 blockers and diuretics. Follow the KDIGO guidelines the target blood pressure < 140/90 mmHg for patients without proteinuria and < 125/75 mmHg in patients with proteinuria is recommended. Better control of post-transplant hypertension improves the long-term graft and patient’s survival.

Introduction

Post-transplant cardiovascular disease

Kidney transplantation is the optimal treatment of patients with ESRD who would otherwise require dialysis. Despite the fact that kidney transplantation reduces the risk of both, cardiovascular morbidity and mortality remain a leading cause of death with functioning graft among kidney transplant recipients (KTR) [1], [2], [3], [4]. Among the traditional and non-traditional risk factors, post-transplant hypertension (PTxH) remains one of the major contributors to the post-transplant cardiovascular morbidity (PTCVM) and mortality and the most common causes of chronic graft dysfunction and kidney transplant failure [5], [6], [7], [8]. Cardiovascular pathology is responsible for approximately 40% of deaths among KTR [9]. The annual risk of fatal and non-fatal cardiovascular events in KTR is 3-5% which is 50-fold higher than in the general population. Both, classical and non-classical cardiovascular factors equally contribute to the increased incidence of PTCVM [10], [11], [12].

Hypertension and Post-Transplant Hypertension

According to the report of Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 8) the new blood pressure classification was introduced bearing in mind the target organ damage and the presence of other factors of comorbidity like Chronic Kidney Disease (CKD), Diabetes, BMI, Hyperlipidemia etc. Thus, Hypertension is defined if office BP is ≥ 140/90 and ambulatory BP ≥ 130/90 in normal persons under the age of 60. The prevalence of PTxH among kidney
Pathogenesis of post-transplant hypertension

The pathogenesis of hypertension during the post-transplant period is multifactorial which include traditional and non-traditional risk factors. Some of them are related to transplant surgery, underlying kidney disease, use of immunosuppression, chronic or acute graft rejections. The majority of these factors are reversible, and some are preventable. They are presented in Table 2.

TABLE 2: Causes of Post-Transplant Hypertension

| Factors          | Examples                                      |
|------------------|-----------------------------------------------|
| Immunosuppression| Cyclosporine, Tacrolimus, Glucocorticoid       |
| Graft disease    | Delayed graft function, Chronic allograft nephropathy, De novo and recurrent glomerular disease, Acute rejection |
| Recipient factors| Underlying kidney disease, Essential hypertension, Native kidney presence, Excessive weight gain, Secondary Hyperparathyroidism |
| Donor factors    | Preexisting donor hypertension, Advanced donor age, Subarachnoidal haemorrhage, Use of right kidney, Female gender |
| Surgery          | Transplant renal artery stenosis, Use of right kidney, Cold and warm ischemia time, Renal artery and vein anastomosis time |

Regarding the mechanism of PTxH it seems that both, volume load and vasoconstriction are present. In the case of renal artery stenosis and CNI dependent hypertension, the vasoconstriction dominates due to the increase of renin-angiotensin system, up-regulation of endothelin-1 and reduction of the bioavailability of nitric oxide. Both cyclosporine and tacrolimus may cause a salt-sensitive form of hypertension with the consecutive fluid overload [26], [27], [28].

Among donor dependent risk factors are already well-confirmed age, history of hypertension, underlying disease (diabetes) vascular disease and genetic predisposition. The use of steroids facilitates sodium and volume retention and contributes to insulin resistance and diabetes.

The positive experience of renal denervation of native kidneys in renal transplant recipients, even in several cases, emphasises the possible role of sympathetic overactivity [29], [30]. The appearance of renal transplant artery stenosis put for sure RA system in the game which could be solved with the appropriate therapeutic procedure. In the cases of recurrent or de-novo glomerulonephritis, classical mechanisms of renal hypertension are involved [31].

Table 1 presents a different classification of Hypertension which is also used in KTR.

| TABLE 1: Definition, types and classification of hypertension |
|----------------------------------------------------------------|
| **Types** | **Values** |
| CBP – Clinical blood pressure | Average BP ≥ 140/90 |
| ABP – Ambulatory blood pressure | Average BP ≥ 130/90 |
| Awake ABP | BP ≥ 140/90 |
| Sleep ABP | BP ≥ 130/90 |
| Normotension | CBP and ABP within the normal range |
| White coat Hypertension | CBP – within hypertensive range |
| Sustained Hypertension | ABP – within hypertensive range |
| Nighttime Hypertension (Nocturnal) | Awake ABP – within normotensive range |
| Daytime Hypertension (Diurnal) | Awake ABP – within hypertensive range |
| All-day Hypertension | Awake ABP – within hypertensive range |

CBP – office control of BP; AMB – 24 h - ambulatory BP control.

recipients is between 55-90% [13], [14]. Significant contributions to the clinical outcome of hypertensive KTR are age, BMI, time after the surgery, gender, presence of chronic allograft nephropathy, cellular and antibody-mediated rejection episodes, use of immunosuppressant, etc.

Regarding hypertension in CKD and transplant patients, KDIGO recommendations are more strict: The BP should be kept below or equal of 130/85 and 125/75 if the patients are proteinuric [15], [16]. The introduction and acceptance of ambulatory blood pressure (ABP) control in the follow up of hypertension in general population as well as in KTR enables more detailed classification of hypertension and therefore a new patient stratification. In KTR both, office and ambulatory BP control should be performed in every day clinical practice. Out of the hypertension classification according to the JNC 8, recently different types of hypertension were clinically introduced as: Masked Hypertension (MH), White Coat Hypertension (WCH), Sustained Hypertension (SH), Isolated Nocturnal Hypertension (INH), Isolated Diurnal Hypertension (IDH), Awake and Asleep hypertension, all with confirmed clinical significance [17], [18], [19], [20]. The most investigated types of hypertension among kidney transplant recipients and CKD patients are WCH and MH. WCH is defined as well-controlled home hypertension but poorly controlled clinic hypertension. MH is the reverse phenomenon, poorly controlled BP at home but normal in the clinic.

The prevalence of MH among KTR is between 23 and 58% with a confirmed harmful effect on graft and patients survival. WCH with a percentage of 4-20% is less important, but still require awareness [20], [21], [22]. The appearance of resistant hypertension (7% of PTxH) is also a confirmed entity which should be treated successfully with carefully chosen antihypertensive drugs [23], [24], [25]. All types of hypertension defined by ABP monitoring are largely investigated in renal transplant recipients and are parts of the efforts to control PTxH on a recommended level according to KDIGO criteria.

Regarding mechanism of PTxH it seems that both, volume load and vasoconstriction are present. In the case of renal artery stenosis and CNI dependent hypertension, the vasoconstriction dominates due to the increase of renin-angiotensin system, up-regulation of endothelin-1 and reduction of the bioavailability of nitric oxide. Both cyclosporine and tacrolimus may cause a salt-sensitive form of hypertension with the consecutive fluid overload [26], [27], [28].

Among donor dependent risk factors are already well-confirmed age, history of hypertension, underlying disease (diabetes) vascular disease and genetic predisposition. The use of steroids facilitates sodium and volume retention and contributes to insulin resistance and diabetes.

The positive experience of renal denervation of native kidneys in renal transplant recipients, even in several cases, emphasises the possible role of sympathetic overactivity [29], [30]. The appearance of renal transplant artery stenosis put for sure RA system in the game which could be solved with the appropriate therapeutic procedure. In the cases of recurrent or de-novo glomerulonephritis, classical mechanisms of renal hypertension are involved [31].
Long term consequences

*Increased cardiovascular morbidity and mortality*

Like in general population many studies confirmed a PTxH as a strong risk factor for ischemic heart disease, congestive heart failure, coronary artery disease, increased arterial stiffness and stroke. The most clinically significant consequence of hypertension is left ventricular hypertrophy, left atrial enlargement and diastolic dysfunction which are responsible for a variety of cardiovascular events after kidney transplantation. Some authors find a strong correlation between left ventricular hypertrophy and post-transplant isolated nocturnal hypertension while 24-hour ABP hypertension and altered Night-Day BP profile are independently associated with Carotid Intima/Media thickness \[32\], \[33\].

*Chronic Graft Dysfunction*

Together with rejection, PTxH is one of the major factors which is responsible for reduced long-term graft and patients survival. A single centre study on long-term kidney transplant survival rate, KTR with diastolic BP of 89-99 mm Hg had statistically decreased GFR compared to recipients with lower blood pressure. Also, recipients with lower blood pressure in the first year have better graft survival. The study of Mange et al. demonstrated the increased risk of graft failure for every 10 mm Hg in SBP and 10 mm Hg in diastolic BP \[34\]. Higher blood pressure correlates with greater rates of progression of decreased renal function.

Chronic allograft nephropathy, renamed by Banff classification with interstitial fibrosis and tubular atrophy (IF-TA), is associated with gradual deterioration in graft function, relevant proteinuria and new or worsening hypertension in the absence of any other worsening factors. Non-HLA antibody-mediated rejection, with an antibody targeting angiotensin II type receptors, develops hypertension secondary to vascular rejection. According to the Collaborative Transplant Study PTxH is an independent risk factor for chronic allograft nephropathy and graft failure \[35\]. Increasing systolic BP was associated with decreased graft survival at any level of diastolic pressure.

Regarding the association with host alloimmune response and acute and chronic rejection, post-transplant hypertension has been confirmed among the rejection of free kidney transplant recipients. However, it could be not excluded that PTH has a deleterious effect of graft small vessels with an increasing of immunogenicity of impaired graft tissue. In addition, some experimental studies confirmed that hypertension increases expression of growth factors and MHC II in chronic allograft nephropathy. PTxH is strongly associated with chronic allograft nephropathy and vice-versa and presents a significant non-immunological risk factor for late graft failure. Altered day-night BP profile, reverse dipper pattern are also associated with early inflammation and constitutes an independent predictor of graft failure \[36\], \[37\], \[38\], \[39\], \[40\].

*Treatment*

*Lifestyle*

The usual recommendations of the Hypertension Associations worldwide may also be applied to kidney transplant recipients. Slightly reduction of salt intake, 30-60 min of moderate daily physical or aerobic activity, maintenance of body mass index between 18-25 kg/m² and keeping the waist circumference under 102 for men and <88 for women. Light dietetic measures could also be recommended as a low-fat diet, moderate alcohol consumption and more vegetables and fruit in everyday nutrition \[27\].

*Treatment target and pharmacological management*

Bearing in mind all the consequences of non-controlled BP in KTR, achievement of target BP level is strongly recommended. The pharmacological treatment should start when office BP is more than 140/90 or ABP more than 130/80 as well as in any case of isolated nocturnal, masked and sustained hypertension or altered day-night time BP profile. The start should be with thiazide diuretics with the addition of Calcium Channel Blockers (CCB), Angiotensin-II Receptor Blockers (ARB) and Angiotensin-II Converting Enzyme (ACE) inhibitors according to the KDIGO and JNC 8 recommendations \[13\], \[15\]. But the regulation and reaching of target BP level are far of an easy task. An average analyses of BP in kidney transplant recipients confirm that despite the whole spectrum of antihypertensives and careful BP measurements, the majority of the patients are still uncontrolled. Whenever we should start our pharmacological approach to the PTxH, hypertensive effects of CNI (especially Cyclosporine A) has to be taken into consideration. The use of other immunosuppressive protocols including mTOR inhibitors or Belatacept instead of CNI may provide better control and beneficial effects on long term graft and patients survival \[27\].

*Invasive procedures*

In patients with proven transplant renal artery stenosis, Percutaneous transluminal angioplasty (PTA) and surgery could be applied if the degree of a
steno
tic lesion is more than 80%. However, it should be
careful in decision because of polar infarcts,
haematoma, intimal flaps, thrombosis and
anastomotic re-stenosis [29, 30].

Renal denervation of the native kidneys is an
interesting and probably promising therapeutic
procedure which can be effective in some individual
cases. A few reports confirmed a beneficial effect of
this procedure, but it is still far of any definitive
conclusion. Interestingly the effect was on nocturnal,
and ABP was some of the non-diaper patients
became dipper [31].

In the recent report from Dallas (USA),
Lerman et al. performed laparoscopic bilateral
nephrectomy in 5 cases of resistant hypertension in
kidney and pancreas transplant recipients. Mean
arterial pressure improved in the next six months after
the surgery and renal function remained stable.
Despite the beneficial results of this small report, there
is no sufficient data to recommend this aggressive
procedure. The future controlled studies should
confirm the justification of surgical approach as a
therapeutic measure [41].

Conclusion

The high prevalence of arterial hypertension in
KTR contributes to chronic graft damage and
significantly decreased graft and long-term patient
survival. Despite the evidence of the adverse effects
of hypertension, BP control has been poor despite the
use of different combinations of antihypertensive
drugs. Adequate diagnosis methods should be
permanently implemented using classical office and
home BP readings. Twenty-four hour ABPM allows
very valuable information on circadian rhythm and
nocturnal blood pressure. PTH remains a very
important issue in clinical follow up of kidney
transplant recipients.

References

1. Naele J and Smith A. Cardiovascular risk factors following renal
transplant. World J Transplant 2015; 5:183-195. https://doi.org/10.5500/wjt.v5.i4.183
PMid:26722646
PMCid:PMC4689929
2. Kono K, Fujii H, Nakai K et al. Relationship Between Type of
Hypertension and Renal Arteriosclerosis in Chronic Glomerular
Disease. Kidney Blood Press Res. 2014; 41:374-383.
https://doi.org/10.1159/000443440
PMid:27232724
3. Stoumpos S, Jardim A and Mark P. Cardiovascular morbidity
and mortality after kidney transplantation. Transplant Int. 2015;
28:10-21. https://doi.org/10.1111/tri.12413
PMid:25081992
4. Svensson M, Jardine A, Fellstrom B et al. Prevention of
cardiovascular disease after renal transplantation. CO-
Transplantation. 2012; 17 (4):393-400.
https://doi.org/10.1097/MOT.0b013e3283560a3b
5. Konstantopoulou AS, Konstantopoulou PS, Papagryiou Ik et
al. Masked, white coat and sustained hypertension : comparison
of target organ damage and psychometric parameters. Journal of
Human Hypertensions. 2010; 24:151-157.
https://doi.org/10.1038/jhh.2009.55
PMid:19571827
6. Soveri I, Holme I, Holdas H et al. A Cardiovascular risk
calculator for renal transplant recipients. Transplantation. 2012;
94:57-62. https://doi.org/10.1097/TP.0b013e3182516edc
PMid:22683851
7. Tainio J, Quist E, Miettinen J et al. Blood Pressure Profiles 5-10
Years After Transplant in Pediatric Solid Organ Recipients. J Clin
Hypertens. 2015; 17:154-161 https://doi.org/10.1111/jch.12465
PMid:25857075
8. Drewz PE, Alper AB, Anderson Ah et al. Masked Hypertension
and Elevated Nighttime Blood Pressure in CKD: Prevalence and
Association with Target Organ Damage. Clin J Am Soc Nephrol.
2016; 11(4):642-52. https://doi.org/10.2215/CJN.08530815
PMid:26912547
PMCid:PMC4822674
9. Malamaci F, Tripodi R, Leonards D et al. Nocturnal
Hypertension and Altered Night-Day BP Profile and Atherosclerosis
in Renal Transplant Patients. Transplantation. 2016; 100:2201-
2211. https://doi.org/10.1097/TP.0000000000001023
10. Apancio LS, Alfie J, Barochiner J, Cuffaro PE, Rada M,
Morales M, Galarza C, Waisman GD. Hypertension: the neglected
complication of transplantation. ISRN Hypertension. 2013; 2013:1-
10. https://doi.org/10.5402/2013/165937
11. Prasad G, Rizicka M, Burns K et al. Hypertension in dialysis
and kidney transplant patients. Can J Cardiol. 2009; 25(5)-309-314.
https://doi.org/10.1016/S0828-282X(09)70495-7
12. Konstantopoulou AS, Konstantopoulou PS, Papagryiou Ik et
al. Masked, white coat and sustained hypertension: comparison of
target organ damage and psychometric parameters. Journal of
Human Hypertension. 2010; 24:151-157.
https://doi.org/10.1038/jhh.2009.55
PMid:19571827
13. James PA, Oparil S, Carter BL, Cushman WC, Dennison-
Himmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie
TD, Ogedegbe O, Smith SC. 2014 evidence-based guideline for
the management of high blood pressure in adults: report from the
panel members appointed to the Eighth Joint National Committee
(JNC 8). JAMA. 2014; 311(5):507-20.
https://doi.org/10.1001/jama.2013.284427
PMid:24352797
14. Sberro-Soussan R, Rabant R, Snaoujdj R et al. Home and
office blood pressure monitoring in renal transplant recipients.
Journal of Transplantation 2012; 2012:1-6.
https://doi.org/10.1155/2012/702316
PMid:22577515
PMCid:PMC3345274
15. Kasiske B, Zeier M, Chapman J et al. KDIGO Clinical practice
guideline for the care of kidney transplant recipients: a summary.
Kidney Int. 2010; 77(4):299-311.
https://doi.org/10.1038/kji.2009.377
PMid:19847156
16. Hamdani G, Nehus E, Hanefold C et al. Ambulatory Blood
Pressure. Left Ventricular Hypertrophy and Allograft Function
in Children and Young Adults After Kidney Transplantation.
Transplantation. 2017; 101:150-156.
https://doi.org/10.1097/TP.0000000000001087
PMid:26895218
PMCid:PMC4990501
17. Kaul A, Sharma RK, Gupta A et al. Spectrum of Hypertension
in post transplant. JAPI. 2010; 58:221-223. PMid:21046874
18. Saxena A, Sharma A. Hypertension in Post-reanl Transplant
Patients. Saudi J Kidney Dis Transpl. 2014; 25:22-28.
https://doi.org/10.4103/1319-2442.124466
PMid:24434378
19. Castillo-Lugo J and Vergne-Marini P. Hypertension in Kidney
Transplantation. Semin Nephrol 2005; 25:252-260.
https://doi.org/10.1016/j.snef.2005.02.009
PMid:16202698
20. Mangray M and Vella J. Hypertension after Kidney Transplant.
Am J Kidney Dis. 2011; 57:331-341.
Hypertension After Kidney Transplantation: Clinical Significance and Therapeutical Aspects

https://doi.org/10.1053/j.ajkd.2010.04.048 PMid:21251543

21. Kaul A, Sharma RK, Gupta A et al. Spectrum of Hypertension in post transplant. JAPI. 2010; 58:221-223. PMid:21046874

22. Mange KC, Cizman B, Joffe M et al. Arterial Hypertension and Renal Allograft Survival. JAMA. 2000; 283:633-638. https://doi.org/10.1001/jama.283.5.633 PMid:10665703

23. Arias M, Fernandez - Fresco G, Gago M, et al. Clinical characteristics of resistant hypertension in renal transplant patients. Nephrol Dial Transplant. 2012; 27(4):S36-S38. https://doi.org/10.1093/ndt/gqs411

24. Tantasattamo E, Ratanasrimetha P, Spanuchart I et al. Hypertension and long-term renal allograft survival. Nephrol Dial Transplant. 2001; 16:105-109. https://doi.org/10.1093/ndt/16.suppl_1.105 PMid:11369835

25. Alizadeh F, Dehghani S, Rahmati M et al. Does hypertension remain after Kidney Transplantation. Acta Medica Iranica. 2015; 53:297-300. PMid:26024705

26. Kaufeld J, Schiffer M, Chatzikyrkou C. Pathogenesis and Management of Hypertension after Kidney Transplantation. Current Hypertension Reviews. 2012; 8:296-301. https://doi.org/10.2174/157340211208040296

27. Ponticelli C, Cucchiari D and Graziani G. Hypertension in kidney transplant recipients. Transplant Int. 2011; 24:523-533. https://doi.org/10.1111/j.1432-2277.2010.01242.x PMid:21382101

28. Pikul K, Dehghani S, Rahmati M et al. Does hypertension remain after Kidney Transplantation. Acta Medica Iranica. 2015; 53:297-300. PMid:26024705

29. Hiremath S, Fergusson D, Doucette S et al. Renin Angiotensin System Blockade in Kidney Transplantation: A Systemic Review of the Evidence. Am J Transplant. 2007; 7:2250-2260. https://doi.org/10.1111/j.1600-6143.2007.01928.x PMid:17845569

30. Dragon D, Muller DN, Braesen JH, et al. Angiotensin II type 1-receptors activating antibodies in renal- allograft rejection. N Engl J Med. 2005; 352(6):558-569. https://doi.org/10.1056/NEJMoa057171 PMid:15703421

31. Dobrowolski L, Bemelman F, ten Berge I et al. Renal Denervation of the Native Kidneys For Drug - resistant Hypertension After Kidney Transplantation. Clin Kidney J. 2015; 8:79-81. https://doi.org/10.1093/ckj/sfu134 PMid:25713714 PMCid:PMC4310436

32. Toprak A, Koc M, Tezcan H et al. Night - time blood pressure load is associated with higher left ventricular mass index in renal transplant recipients. Journal of Human Hypertension. 2003; 17:239-244. https://doi.org/10.1038/sj.jhh.1001536 PMid:12692568

33. Demirkol O, Orcu M, Ikizmir B et al. Ambulatory Blood pressure Monitoring and Echocardiographic Findings in Renal Transplant Recipients. J Clin Hypertens. 2016; 18:766-771. https://doi.org/10.1111/jch.12755 PMid:26689296

34. Mange KC, Cizman B, Joffe M et al. Arterial Hypertension and Renal Allograft Survival. JAMA. 2000; 283:633-638. https://doi.org/10.1001/jama.283.5.633 PMid:10665703

35. Opelz G, Wujciak T, Ritz E et al. Association of chronic kidney graft failure with recipient blood pressure. Collaborative Transplant Study. Kidney Int. 1998; 53:217-222. https://doi.org/10.1046/j.1523-1755.1998.00744.x PMid:9450322

36. Modena FM, Hostetter TH, Salahudeen AK, Najarian JS, Matas AJ, Rosenberg ME. Progression of kidney disease in chronic renal transplant rejection. Transplantation. 1991; 52(2):239-244. https://doi.org/10.1097/00007890-199108000-00011 PMid:1871796

37. Fernandez-Fresneda G, Palomar R, Escallada R et al. Hypertension and long-term renal allograft survival. Nephrol Dial Transplant. 2001; 16:105-109. https://doi.org/10.1093/ndt/16.suppl_1.105 PMid:11369835

38. Solez K, Colvin RB, Racusen LC, et al. Banff’05 meeting report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy (CAN). Am J Transplant. 2007; 7(3):518-526. https://doi.org/10.1111/j.1600-6143.2006.01688.x PMid:17352710

39. Massy Z, Guijarro C, Wiederkehr M et al. Banff’05 meeting report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy (CAN). Am J Transplant. 2007; 7(3):518-526. https://doi.org/10.1111/j.1600-6143.2006.01688.x PMid:17352710

40. Schindler R, Tullius S, Tanriver Y et al. Hypertension increases expression of growth factors and MHC II in chronic allograft rejection: Immunologic and nonimmunologic risk factors. Kidney Int. 1996; 49:518-524. https://doi.org/10.1038/1755.2006.00011

41. Lerman M, Hinton S and Aronoff R. Bilateral native nephrectomy for refractory hypertension in kidney transplant recipients. International Journal of Surgery Case Reports. 2015; 15:127-129. https://doi.org/10.1016/j.ijscr.2015.08.001 PMid:26348934 PMCid:PMC4601950